Jeevan Scientific receives US FDA report with zero observations
- Jeevan Scientific Technology received a clean US FDA Establishment Inspection Report
- The bioanalytical facility in Hyderabad had zero observations during the July 2026 audit
- The EIR was officially released on September 30, 2026, under 21 CFR 20.64(d)(3)
*this image is generated using AI for illustrative purposes only.
Jeevan Scientific Technology Limited has received a clean Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its bioanalytical facility in Hyderabad, with zero observations recorded.
The inspection, conducted between July 20 and July 24, 2026, concluded successfully under 21 CFR 20.64(d)(3). The regulatory body released the final EIR on September 30, 2026, confirming no deficiencies were found during the review of the Manikonda unit.
Inspection details
The US FDA inspected the company's bioanalytical facility located at Manikonda, Hyderabad. The closure of the inspection with "No Observations" signifies that the facility met the required standards without any noted deviations or critical issues during the audit period.
| Detail | Information |
|---|---|
| Facility Location | Manikonda, Hyderabad |
| Inspection Dates | July 20 to July 24, 2026 |
| EIR Release Date | September 30, 2026 |
| Observation Status | Zero observations |
| Regulatory Reference | 21 CFR 20.64(d)(3) |
Regulatory compliance
This announcement follows an earlier disclosure made by the company on July 24, 2026. The receipt of a clean EIR is a significant compliance milestone, indicating that the company's quality systems and operational procedures aligned with US FDA expectations during the recent review.
Historical Stock Returns for Jeevan Scientific Technology
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.75% | +7.36% | +9.28% | +19.48% | +45.86% | 0.0% |
How will the clean EIR impact Jeevan Scientific Technology Limited's ability to secure new bioanalytical contracts with US-based pharmaceutical clients?
What is the expected timeline for the company to integrate this compliance status into its upcoming quarterly revenue guidance?
Will this regulatory success prompt the company to expand capacity at the Hyderabad facility to meet increased demand?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
